Immunex Shares Soar On Enbrel Data

15 September 1997

Immunex Corp's tumor necrosis factor receptor Enbrel has provedeffective in the treatment of rheumatoid arthritis, according to Phase III data. Shares in the company soared on the day of the announcement (September 11), up $12.63 to $56.13, and even increased the following day by another $4.50 to close at $60.38.

234 patients with severe rheumatoid arthritis who had failed all other disease-modifying antirheumatic drugs were enrolled in the trial and were randomized to receive either 10mg or 25mg of Enbrel or placebo via injection twice weekly for a period of six months. Patients receiving Enbrel experienced significantly better symptom improvements (measured by composite scales called American College of Rheumatology 20 and ACR 50) than placebo at both three- and six-month endpoints.

Analysis of the data is ongoing, according to a company spokesman. However, the percentage change in symptom improvement is similar to that found in an earlier Phase II study, he said, which showed that at three months, 75% of the patients in the group assigned to the most effective dose (16mg/m2) had improvement of 20% or more in symptoms, versus 14% in the placebo group (Marketletter July 28). Complete data from the Phase III study will be presented at the ACR meeting in November, says the company.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight